SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGMED - GenoMed Inc.


Previous 10 Next 10 
From: Tadsamillionaire10/18/2005 3:20:10 PM
   of 347
 
GMED mentioned with the big boys,

>>The technology for producing a vaccine exists, but manufacturers will probably have to wait until the exact pandemic strain is known before they can build a vaccine to fight it. Currently, a few companies like GlaxoSmithKline, Chiron, Sanofi Pasteur and GenoMed are working on it, but it will take up to six months for a vaccine to be produced in great volume. Even then, it will be just a fraction of the amount needed globally.<<

Production of vaccine in bulk may take 6 mths
JEETHA D?€™SILVA AND CHHAVI DANG

TIMES NEWS NETWORK[ SATURDAY, OCTOBER 15, 2005 12:59:08 AM]
NRI Special Offer!
MUMBAI: As the threat of bird flu hovers over India, it is apparent that some drastic action is needed as the flu vaccine is falling appallingly short. What complicates the situation is that the next pandemic may be caused by a new strain of the influenza virus. The 60 deaths that have been reported so far are those that have been due to the H5N1 strain that causes avian influenza. At present, there is no specific vaccine to prevent avian influenza in human beings.

The technology for producing a vaccine exists, but manufacturers will probably have to wait until the exact pandemic strain is known before they can build a vaccine to fight it. Currently, a few companies like GlaxoSmithKline, Chiron, Sanofi Pasteur and GenoMed are working on it, but it will take up to six months for a vaccine to be produced in great volume. Even then, it will be just a fraction of the amount needed globally.

Oseltamivir, sold by global pharma major Roche under the brand name Tamiflu, is the most effective drug for the prevention and treatment of human influenza. This drug is not available in the country, though sources say that the company plans to launch the product in India shortly.

One of the early measures many governments are adopting to check the spread of the virus is surveillance of poultry and migratory birds. The department of animal husbandry claims that it has been conducting surveillance checks for the last four years, not only on domestic birds but also on the migratory birds.

Poultry sales have so far not been affected. A distributor for a leading poultry firm told ET that chicken sales have not shown any signs of falling. “No evidence of avian influenza has been found in poultry or migratory birds,” said Santanu Kumar Bandyopadhyay, commissioner, animal husbandry department.

economictimes.indiatimes.com

TAKEN FROM RB BOARD....
ragingbull.lycos.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Tadsamillionaire who wrote (285)10/22/2005 4:05:18 AM
From: jmhollen
   of 347
 
I wish the folks at GMED and the folks at NNVC would get together and chat.

I'm seeing some valuable synergies here.

John :-)

.

Share RecommendKeepReplyMark as Last Read


From: jmhollen10/25/2005 11:04:55 AM
   of 347
 
GenoMed CEO Honored for Innovation in Healthcare by St. Louis Business Journal

Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com

ST. LOUIS--October 25, 2005--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health, announced today that its CEO, David W. Moskowitz MD, has been nominated as a finalist in the 2005 Health Care Heroes sponsored by the St. Louis Business Journal.


Now in its second year, the Health Care Heroes of St. Louis is an annual celebration organized by the St. Louis Business Journal to tell the stories of those who have benefited from the innovation and dedication of heroes in the health care profession. The event will be held November 10, 2005 in St. Louis (http://stlouis.bizjournals.com/stlouis/event/1916).

GenoMed currently earns revenues from its published protocols to reverse chronic kidney failure due to diabetes or high blood pressure, and delay progression of emphysema. These diseases affect 90 million Americans. The Company is currently conducting free trials for many additional diseases, including Parkinson's disease, Alzheimer's disease, most cancers, and viral diseases including West Nile virus encephalitis, regular influenza, and avian influenza.

Any one interested in signing up for GenoMed's trial just needs to go to GenoMed's website (www.genomed.com), and follow the links for the "Flu trial." The trial documents are self-explanatory.

About GenoMed

GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975).
.

Share RecommendKeepReplyMark as Last Read


From: jmhollen11/14/2005 2:02:26 PM
   of 347
 
"Cytokine Storm" Paper Confirms GenoMed's Approach to Avian Flu

Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com


ST. LOUIS—November 14, 2005--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health, announced today that its approach to avian influenza was confirmed last week by a Hong Kong research group who found that the avian influenza virus induces a "cytokine storm" in human lung cells grown in tissue culture.

Dr. J.S.M. Peiris and colleagues published last week in Respiratory Research that avian influenza (H5N1) viruses isolated from dead patients cause lung cells to produce many more pro-inflammatory molecules, called "cytokines," than regular influenza A viral strains. This research confirms GenoMed's hypothesis that the host's immune response to the virus is what causes death, not the replication of the virus itself.

About GenoMed

GenoMed's broad-spectrum anti-viral approach is specifically mentioned in BioShield II, (see Section 2151 of Senate bill S. 975). GenoMed uses already existing, safe medication present in every drug store and hospital in the world. GenoMed is now charging a one-time license fee of US $10 to access its treatment approach, which is patent-pending globally. Please see www.genomed.com for details.

.

Share RecommendKeepReplyMark as Last Read


From: jmhollen11/28/2005 7:40:19 PM
   of 347
 
GenoMed Considers Offering Low-Cost Health Insurance to America's Uninsured

Contact: David Moskowitz MD CEO, GenoMed, Inc. Tel. 314-983-9933 dwmoskowitz@genomed.com


ST. LOUIS, November 28, 2005 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management company, announced today that it is considering partnering to offer a low-cost health insurance product to compete for the uninsured market.

By avoiding expensive hospitalizations for diabetes, high blood pressure, and emphysema, GenoMed can already slash healthcare costs for cardiovascular disease. Two-thirds of Americans die from cardiovascular disease, and one third from cancer. With its Healthchip® to serve as an early warning system for the top six common cancers in whites, breast, colon, lung, ovarian, pancreatic, and prostate, GenoMed has taken the first step towards curing cancer.

The company wants to pass these savings on to the consumer in the form of markedly lower premiums. Currently, health insurance costs $6,000 a year, but life expectancy from cardiovascular disease and cancer is still poor. GenoMed thinks it can provide better patient outcomes for up to 40% less. The company is currently looking for two other partners to provide low cost health insurance: a mail-order pharmacy to supply drugs inexpensively, and an insurance carrier for catastrophic hospitalization.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "If hospitalization can be avoided for most patients by judicious use of outpatient medications and tests, then insurance rates can be lowered considerably. Hospitalization will become the exception, not the norm, and catastrophic hospitalization insurance rates should apply. This is the whole promise of medical genomics and preventive molecular medicine."

GenoMed hopes to offer an insurance product inexpensive enough to attract America's 45 million uninsured patients. Given the rising cost of healthcare, other payors should soon follow as customers, including employers, state Medicaid programs, Medicare, overseas National Health Services, etc.

About GenoMed™

GenoMed is leading the clinical revolution which knowledge of disease genes makes possible. GenoMed is currently marketing its protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema. The company plans to increase the scope and predictive power of its Healthchip® by collecting patient samples from additional types of cancer, and additional ethnic groups. The company is finding that its science requires it to also discover new business models.


Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jmhollen who wrote (289)2/9/2006 11:29:19 AM
From: Tadsamillionaire
   of 347
 
GenoMed's Formula for Better Healthcare at Half the Price = GenoMed + President Bush's HSAs
Wednesday February 1, 9:30 am ET

ST. LOUIS, Feb. 1 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management company, announced today that it can deliver better healthcare for half the cost, if coupled with the President's health savings accounts (HSAs).

biz.yahoo.com

Thanks to President Bush's HSAs, GenoMed can now offer an insurance plan inexpensive enough to attract most of America's 46 million uninsured patients. Given the high cost of healthcare, other customers should quickly follow, including large employers, state Medicaid programs, Medicare, overseas National Health Services, etc.

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire2/21/2006 3:46:56 PM
   of 347
 
GenoMed Trial Results: HIV -- Viral Load Goes to Zero
ST. LOUIS, Feb. 21 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is public health, announced today that its first HIV patient had his viral load fall to zero after starting GenoMed's trial.

The patient is a 54 year old African American man who was diagnosed with HIV 2 years ago. He was being treated with a standard triple-drug 'cocktail' and had a stable viral load when he began GenoMed's trial this past summer, as shown in the following table:

Date HIV viral load (copies of the virus per milliliter)
4/11/05 160
6/23/05 228
7/19/05 225
8/29/05 START OF GenoMed's TRIAL
11/2005 0
12/2005 0
1/2006 Switch from Sustiva(R) to Kaletra(R), which had failed this
patient in the past
2/14/06 109

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, 'In this trial, we've been using blood pressure pills, for which we have a 'use' patent that is pending. Why this should work is as interesting as the fact that it has worked. It points out the clinical reliability of the genomic epidemiologic data that we published in 2002.'

Continued Dr. Moskowitz, 'Our approach, if it is confirmed in other HIV patients, may help with the chronic treatment of HIV patients. Our earlier data suggests that this approach may also decrease infectivity of the HIV virus in the first place. Because these drugs already are on the shelves in most pharmacies on earth, including Africa, it could be quite helpful in the global struggle against HIV/AIDS.'

Share RecommendKeepReplyMark as Last Read


From: jmhollen3/1/2006 1:16:15 PM
   of 347
 
GenoMed Awarded Second Patent, for Avoiding Dialysis in Acute Kidney Failure

Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com


ST. LOUIS—March 1, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, announced today that it received its second patent (US Patent #6,998,404) for the "Treatment or prevention of acute renal failure." Acute kidney failure usually happens when a patient gets dehydrated.

Acute kidney failure currently requires a lengthy hospital stay, often involving daily kidney dialysis in the Intensive Care Unit. In addition to the extra cost, acute kidney failure also carries up to a 50% risk of dying. Avoiding dialysis in the first place should greatly improve patient survival and lower healthcare costs.

Said David Moskowitz, MD, FACP, GenoMed's CEO and Chief Medical Officer, "Our patented protocol should be of immediate use to every hospital around the world, especially in places without convenient dialysis. It should be especially useful in disaster zones like New Orleans and earthquakes, as well as the battlefield, where people get dehydrated and go into kidney failure, but can't be dialyzed right away."

Added Dr. Moskowitz, "In a pilot series, our protocol was safe and effective in a dozen newborns and nine adults, including several patients with combined liver and kidney failure, so-called hepato-renal syndrome. We invite interested physicians to collaborate with us in extending these results to additional patients."

About GenoMed

GenoMed finds disease-causing genes, and uses this knowledge to devise new treatment strategies. The Company uses already existing medications whenever possible to maximize safety as well as minimize development costs. GenoMed then passes these savings on to healthcare consumers. GenoMed's treatment for acute kidney failure uses an already existing intravenous medication. An oral form may also work, which would be especially useful in natural disasters and the battlefield.


Share RecommendKeepReplyMark as Last Read


From: jmhollen3/8/2006 3:16:13 PM
   of 347
 
GenoMed Announces Healthchip® to Predict Six Common Cancers Including Lung Cancer

Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com

ST. LOUIS—March 8, 2006--GenoMed (OTC Pink Sheets GMED.PK), a Next Generation Disease Management company whose business is public health™, announced today that it has developed a genomic test for predicting six common cancers: breast, colon, lung, ovarian, pancreatic, and prostate.

GenoMed's test, called the Healthchip®, consists of several hundred single nucleotide polymorphisms (SNPs, pronounced "snips"). Although several more years of tests will be required before FDA approval, the Healthchip® currently identifies patients correctly 85% of the time.

The Healthchip® allows patients to focus their preventive efforts on a single organ. A patient identified as "high risk" for lung cancer, such as Dana Reeve, could get an MRI of her lungs every year or two with the hope that any tumor would be detected at an early enough stage that it could be completely cut out surgically for a cure. Patients at high risk for a particular cancer would need to engage in lifelong surveillance, just as patients at risk for colon cancer undergo repeated colonoscopies their entire life.

Many of the genes that cause cancer will also make excellent targets for new chemotherapy drugs. Because they are more specific to the cancer process, these drugs promise to be less toxic than the currently employed general cellular poisons.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Screening for the six cancers is currently possible in Caucasians only. We would like to extend this work to African American, Asian, and Hispanic patients. We would also like to extend our Healthchip® to include more than the top six solid cancers in adults, as well as cancers in children. Anyone interested is encouraged to contact me at 314.983.9933 or by e-mail, dwmoskowitz@genomed.com ."

About GenoMed

GenoMed finds disease-causing genes, and uses this knowledge to devise new treatment strategies. The Healthchip® is available on a research basis only. Because of genotyping costs, the Healthchip® costs $1,000 for research participants.
.

Share RecommendKeepReplyMark as Last Read


From: jmhollen3/9/2006 3:21:13 PM
   of 347
 
GenoMed's Message for First World Kidney Day: 90% of Kidney Failure in U.S. Can Be Prevented Now

Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com


ST. LOUIS—March 9, 2006--GenoMed (OTC Pink Sheets GMED.PK), a Next Generation Disease Management company whose business is public health, announced today on the eve of the first World Kidney Day that it can prevent up to 90% of chronic kidney disease in the United States.

In September, 2002, GenoMed published a peer-reviewed medical article showing how chronic kidney disease due to diabetes and high blood pressure could be prevented in a total of 1,000 white and black male veterans from St. Louis. In unpublished data, GenoMed's Chief Medical Officer has prevented kidney failure in 350 Hispanic men and women followed since July, 2001 at a free clinic in St. Louis (La Clinica).

Diabetes and high blood pressure account for 90% of kidney dialysis patients in the United States. Medicare currently spends about $25 billion annually on dialysis and kidney transplantation for about 300,000 patients with kidney failure. Since 2000, kidney failure has been increasing at an epidemic rate, 7% per year.

Recovery of kidney function is not possible once a patient is on dialysis. There is a very narrow window of opportunity when prevention is possible: before the patient has lost more than half of their kidney function, that is, when their serum creatinine is still less than 2. (A normal serum creatinine is 1; when it's 10, it's time for dialysis).

Patients are still being seen by their primary care providers below a serum creatinine of 2, and haven't yet seen a kidney doctor. So education of patients and their primary care providers--general internists and family practitioners--is absolutely critical.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "It is fitting that the first World Kidney Day should fall during America's National Patient Safety Week. People of color throughout the world, including the U.S., are even more affected by kidney failure than whites."

Dr. Moskowitz continued, "I am deeply honored to be named today a Defender of Patient Safety by Missouri Watch (http://www.missouriwatch.net). The only thing needed to keep patients off dialysis is just to let them know that it can be done. It's unfortunate that it has taken over three years for the news to get this far. A whole generation of patients who could have been kept off the kidney machine three years ago has gone on to dialysis and an early death."

About GenoMed

GenoMed discovers the genes that cause disease and uses this knowledge to improve patient outcomes. The company's primary commitment is to public health, which involves public education. In addition to having treatments for acute and chronic kidney failure, emphysema, and autoimmune diseases such as psoriasis and alopecia, GenoMed has developed a broad-spectrum anti-viral approach that is expected to work for avian influenza, and has already worked for West Nile virus. GenoMed's anti-viral treatment is specifically mentioned in BioShield II, scheduled for debate this summer in the US Senate (see Section 2151 of Senate bill S. 975). To enroll in GenoMed's free clinical trial for avian influenza or West Nile virus, which uses existing, extremely safe medication already present in every drug store on earth, just go to www.genomed.com and click on the link for either trial.


Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10